Tapan Maniar

Tapan Maniar is the Chief Business Officer at Verdiva Bio, a clinical-stage cardiometabolic company based in Boston, Massachusetts. He assumed this role in January 2025 alongside the company's $411 million Series A launch, previously serving as Chief Business Officer at Aiolos Bio following its $245 million Series A. Maniar was formerly a Principal at Bain Capital Life Sciences, and he held clinical leadership roles including Chief Medical Officer at AvenCell and Senior Vice President of Clinical Development at Dragonfly Therapeutics. His earlier career includes serving as Global Development Lead for BLINCYTO at Amgen, heading business development for technology platforms at Genentech, and working at McKinsey & Company. Holding an MD from the University of Pennsylvania and a Ph.D. from The Rockefeller University, Maniar focuses on advancing clinical development and corporate strategy across the biotechnology sector.